BRYOSTATIN-1 ENHANCES LYMPHOKINE-ACTIVATED KILLER SENSITIVITY AND MODULATES THE BETA(1) INTEGRIN PROFILE OF CULTURED HUMAN TUMOR-CELLS

Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of human and murine cytotoxic T lymphocytes, and in the growth and differentiation of tumor cells. Bryostatin 1 has immunomodulating and antitumor properties as demonstrated by preclinical and clinical studies. Here we report that bryostatin 1 increases the susceptibiliy to lymphokine activated killers and modifies the pattern of beta(1) integrin expression of human tumor cells. On the basis of these results the use of bryostatin 1 in combination with immunostimulating cytokines such as interleukin-2 in the treatment of human cancer is suggested.